Context Therapeutics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Context Therapeutics Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 24, 2026, and is seeking approval to increase its authorized common stock.
NASDAQ
Context Therapeutics Inc. has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.
NASDAQ
DEF: Context Therapeutics Seeks Stockholder Approval for Reverse Stock Split to Regain Nasdaq Compliance
Context Therapeutics is asking stockholders to approve a reverse stock split to increase its stock price and maintain its Nasdaq listing.
NASDAQ
Context Therapeutics Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
Context Therapeutics is asking stockholders to approve an amendment to its corporate charter to increase the number of authorized common shares from 100 million to 200 million.
NASDAQ
Context Therapeutics Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
DEF 14A: Context Therapeutics Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals
Context Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, featuring proposals for director elections and ratification of the company's independent accounting firm.